Automation synthesis modules review.

The introduction of (68)Ga labelled tracers has changed the diagnostic approach to neuroendocrine tumours and the availability of a reliable, long-lived (68)Ge/(68)Ga generator has been at the bases of the development of (68)Ga radiopharmacy. The huge increase in clinical demand, the impact of regulatory issues and a careful radioprotection of the operators have boosted for extensive automation of the production process. The development of automated systems for (68)Ga radiochemistry, different engineering and software strategies and post-processing of the eluate were discussed along with impact of automation with regulations.

[1]  C. Shealy,et al.  GALLIUM-68 AS A SCANNING AGENT FOR INTRACRANIAL LESIONS. , 1964, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  W. H. Knapp,et al.  68Ga-labelled DOTA-derivatised peptide ligands , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  C Decristoforo,et al.  Full automation of (68)Ga labelling of DOTA-peptides including cation exchange prepurification. , 2010, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[4]  Wolfgang A Weber,et al.  PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference , 2011, The Journal of Nuclear Medicine.

[5]  Markus Jahn,et al.  Processing of Generator-Produced 68Ga for Medical Application , 2007, Journal of Nuclear Medicine.

[6]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.

[7]  E. Deutsch.  "Clinical PET: its time has come?". , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  Sudipta Chakraborty,et al.  177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. , 2004, Nuclear medicine and biology.

[9]  J. Šimeček,et al.  TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals. , 2011, Chemistry.

[10]  G. Cicoria,et al.  Radiolabelling, quality control and radiochemical purity assessment of the Octreotide analogue 68Ga DOTA NOC. , 2008, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[11]  Roland Haubner,et al.  Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system , 2011, Nuclear medicine communications.

[12]  Guy Bormans,et al.  Optimal buffer choice of the radiosynthesis of 68Ga–Dotatoc for clinical application , 2010, Nuclear medicine communications.

[13]  P. Riss,et al.  The renaissance of the ⁶⁸Ge/⁶⁸Ga radionuclide generator initiates new developments in ⁶⁸Ga radiopharmaceutical chemistry. , 2010, Current topics in medicinal chemistry.

[14]  Marion de Jong,et al.  Radiolabelling DOTA-peptides with 68Ga , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  Roland Haubner,et al.  A fully automated synthesis for the preparation of 68Ga-labelled peptides , 2007, Nuclear medicine communications.

[16]  B. Långström,et al.  Microwave-supported preparation of (68)Ga bioconjugates with high specific radioactivity. , 2004, Bioconjugate chemistry.

[17]  R L Hayes,et al.  Bone scanning with gallium-68: a carrier effect. , 1965, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.